Hyperferritinemia and diagnosis of type 1 Gaucher disease

Giacomo Marchi1 | Fabio Nascimbeni2 | Irene Motta3,4 | Fabiana Busti1 | Francesca Carubbi2 | Maria Domenica Cappellini3,4 | Antonello Pietrangelo5,6 | Elena Corradini5,6 | Alberto Piperno7 | Domenico Girelli1

1EuroBloodNet Referral Center for Iron Disorders and Gruppo Interdisciplinare Malattie del Ferro, Internal Medicine Unit, Azienda Ospedaliera Universitaria Integrita, Verona, Italy
2Regional Referral Center for Lysosomal Storage Diseases, Division of Internal Medicine and Metabolism, Azienda Ospedaliero-Universitaria di Modena - Ospedale Civile, University of Modena and Reggio Emilia, Modena, Italy
3Department of Medicine and Medical Specialties, Fondazione IRCCS Cà Granda, Milan, Italy
4Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
5Division of Internal Medicine and Center for Hemochromatosis and Heredometabolic Liver Diseases, EuroBloodNet Referral Center for Iron Disorders, Azienda Ospedaliero-Universitaria di Modena - Policlinico, Modena, Italy
6Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
7EuroBloodNet and MetaBERN Referral Center, Department of Medicine and Surgery, University of Milano-Bicocca, Medical Genetics, ASST Monza - S. Gerardo Hospital, Monza, Italy

Correspondence
Elena Corradini, Division of Internal Medicine and Center for Hemochromatosis and Heredometabolic Liver Diseases, EuroBloodNet Referral Center for Iron Disorders, Azienda Ospedaliero-Universitaria di Modena - Policlinico, 41124 Modena, Italy.
Email: elena.corradini75@unimore.it

1 | CASE PRESENTATION

A 61-year-old Caucasian man presented with persistent hyperferritinemia known since his forties in the presence of components of metabolic syndrome. History revealed longstanding obesity, with maximum weight and BMI of 100 kg and 32 kg/m², respectively. At the age of 45 years, routine blood examination showed marked hyperferritinemia (1738 μg/L) with normal transferrin saturation (TSat 41%), very mild thrombocytopenia (140 × 10⁹/L), normal Hb (139 g/L) and white blood cell count (8.93 × 10⁹/L), and polyclonal hypergammaglobulinemia (21.5%). He also had low HDL cholesterol (0.8 mmol/L), mild hypertriglyceridemia (2.33 mmol/L), impaired fasting glucose (5.66 mmol/L), and oral glucose tolerance test (OGTT) consistent with glucose intolerance (glucose 9.49 mmol/L at 2 hours). Liver function tests were normal, as well as C-reactive protein, coagulation, renal and thyroid function tests. At that time, he reported an unbalanced diet with moderate alcohol consumption, sedentariness, and positive family history for type 2 diabetes mellitus. Abdominal ultrasonography (US) showed mild liver enlargement with increased echogenicity consistent with moderate steatosis; the major diameter of the spleen was 12.4 cm; no signs of portal hypertension were detected. Liver biopsy demonstrated micro-macrovacular steatosis in 50% of hepatocytes, and hypertrophic Kupffer cells with mild siderosis (Figure 1).

A first-level genetic test for HFE-hemochromatosis was negative, only showing heterozygosity for the H63D variant. Sequencing of the SLC40A1 gene (encoding ferroportin) did not reveal pathogenic mutations. A provisional diagnosis of dysmetabolic iron overload syndrome (DIOS) was suggested, and lifestyle changes as well as alcohol withdrawal were recommended.

Initially, Gaucher disease (GD) was not suspected. The patient had ≥2 alterations of the metabolic syndrome, liver steatosis and normal TSat, fitting the criteria for the diagnosis of DIOS, which represents a far more frequent cause of hyperferritinemia than GD. A possible Ferroportin Disease, suggested by iron accumulation in Kupffer cells, was ruled out by SLC40A1 sequencing.

In the following 15 years, the patient lost weight (8 kg, leading to BMI reduction to 28 kg/m²), and substantially improved his metabolic profile (fasting glucose 4.88 mmol/L, OGTT normalization, HDL cholesterol 1.39 mmol/L, triglycerides 0.93 mmol/L); he also underwent irregular phlebotomies (total n = 12). Nonetheless, serum ferritin was only mildly reduced (1056 μg/L). Of note, hypergammaglobulinemia (21%) was confirmed, and platelet count further decreased.
The patient reported worsening back and knee pain. Lumbar spine MRI revealed diffuse bone marrow infiltration, multiple bulging disks, and osteophytosis.

The initial diagnosis of DIOS was questioned since a more pronounced decrease of serum ferritin would have been expected due to the substantial metabolic improvement. Considering the whole clinical phenotype characterized by worsening thrombocytopenia, polyclonal gammopathy, and bone pain, GD was eventually suspected and confirmed by the reduced $\beta$-glucocerebrosidase activity, on both dried blood spot (DBS) and leukocytes (0.6 nmol/mg/h; normal range 10-30).

$\text{GBA1}$ sequencing detected homozygosity for the pathogenic N370S mutation. A critical revision of the liver biopsy allowed re-defining the "hypertrophic" Kupffer cells as Gaucher cells.

Abdominal MRI showed hepatomegaly (2043 mL; normal value <2000), normal liver iron concentration (35 ± 20 μmol/g, normal value <36), and mild splenomegaly (510 mL; normal value 110-340) with several nodular lesions (the so-called "Gaucheromas") (Figure 2).

Further disease staging revealed increased chitotriosidase (493 nmol/mL/h, normal value 43 ± 23) and glucosylsphingosine (93 ng/mL; normal value <4.8) levels. Femoral and pelvic MRI showed diffuse bone marrow infiltration similar to that observed in the lumbar spine, and consistent with the pain sites reported by the patient. Lumbar and femoral densitometry excluded osteoporosis and osteopenia. Enzyme replacement therapy (ERT) was started and, after 18 months, skeletal and visceral involvement improved, platelet count was $167 \times 10^9$/L, ferritin levels decreased to 430 μg/L (without further phlebotomies), and gammaglobulin to 19.2%.

Gaucher Disease is frequently underdiagnosed because of lack of awareness, even when all typical clinical signs and symptoms are present. This case was challenging since the classical hematological signs of GD were initially mild and incomplete (normal Hb, barely detectable thrombocytopenia and splenomegaly). Over the 15 years follow-up, the platelet count dropped and the patient developed severe and symptomatic bone marrow infiltration, justifying the starting of ERT. Regarding hyperferritinemia, it was initially attributed to metabolic syndrome, and improvement of lifestyle was recommended. Of note, obesity is uncommon in untreated GD patients.

We subsequently collected 8 GD type 1 (GD1) patients referred to four Italian specialized centers for iron disorders, because of "unexplained hyperferritinemia" (Table 1). All subjects were Caucasians, with a median age at diagnosis of 45 years. Both sexes were represented (five males and three females). At least one N370S mutation was present in seven out of eight patients. Median ferritin was 1285 μg/L, median TSat 27%, and only one of the patients had evidence of significant IO, in line with previous case series. Noteworthy, the classical GD hematological alterations were mild or even absent at first evaluation, underscoring the need for a high degree of suspicion.

Figure 1. Liver histology in hematoxylin–eosin 4x (A) and 40x (B) and in Perls staining 40x (C). Preserved acinar structure with micro-macrovesicular steatosis in 50% of hepatocytes (A, B). Hypertrophic Kupffer cells with siderosis (Brissot grade 3/20) (C) [Color figure can be viewed at wileyonlinelibrary.com]

Figure 2. MRI T2-weighted sections showing hepatomegaly and splenomegaly with multiple Gaucheromas.
### TABLE 1  
Details of patients in the case series: diagnosis of GD in patients initially referred for "unexplained hyperferritinemia" in four Italian referral centers for iron disorders: MO = Modena; VR = Verona; MZ = Monza; MI = Milan. ^ normal beta-glucocerebrosidase activity: 18.4 ± 6.8 nmol/mg/hr. § underwent iron depletion by phlebotomies (3-4 per month, total iron removed 7 g)

| Pt ID | GD genotype | Gender | Age at GD diagnosis; age at first detection of hyper-ferritinemia | Ferritin (μg/L); TSAT | HFE | LIC at MRI | Liver biopsy | Splenomegaly (MRI-spleen volume; US-maximum diameter) | PLTs (x 10^9/L) | Hb (g/L) | Other GD manifestations | Other concurrent medical conditions |
|-------|-------------|--------|---------------------------------------------------------------|------------------------|-----|------------|-------------|-------------------------------------------------|----------------|---------|------------------------|----------------------------------|
| MO1   | N370S/ N370S | M      | 61; 45                                                        | 1738 (age 45), 1056 (age 61); 41% | H63D hetero | Normal (35 ± 20 μM/g) (after therapeutic phlebotomy 15 years earlier) | Hypertrophic Kupffer cells with mild siderosis | 510 mL; 12.4 | 140-111 | 139 | Nodular splenomegaly, hepatomegaly, polyclonal gammopathy, fatigue, bone pain and bone marrow infiltration | Obesity, metabolic syndrome, liver steatosis |
| VR1   | N370S/ N370S | M      | 60; 56                                                        | 1470; 35%              | S65C hetero | 80 ± 30 μM/g pre-SRT, 47 ± 30 after 1 year of SRT | NA | 371 mL; 12.7 cm | 116 | 144 | Mild hepatomegaly, Parkinson, fatigue, chronic bone pain, bone marrow infiltration | Type 2 diabetes, hypercholesterolemia (anamnestic) |
| VR2   | N370S/ N370S | F      | 23; 22                                                        | 600; 15%               | Wild type | <36 μM/g pre-SRT | NA | 400 mL; 13.9 cm | 118 | 121 | Hepatomegaly, reduced bone mass, fatigue | none |
| MZ1   | N370S/ F2131 | M      | 55; 55                                                        | 1965; 28%              | Wild type | NA | Mixed iron overload, prevalent in Kupffer cells; presence of Gaucher cells | NA; 14 cm | 112 | 138 | Hepatomegaly | alcohol intake 30 g/day |
| MZ2   | N370S/x (enzyme activity 1.1 nmol/mg/hr) | F | 48; 45                                                        | 928; 25%               | Wild type | NA | Unremarkable except for presence of Gaucher cells | NA; 12 cm | 109 | 123 | Hepatomegaly | mild overweight |
| MZ3   | N370S/ G362* | M      | 42; 40                                                        | 1101; 18%              | Wild type | NA | NA | NA; 19 cm | 42 | 125 | Leucopenia 3.11 × 10^9/L; hepatomegaly | Liver steatosis |
| M1    | N370S/ G377S | F      | 33; 27                                                        | 443; 26%               | NA | NA | NA | NA; 13 cm | 130 | 112 | Bone marrow infiltration | none |
| M2    | L444P/ A456P | M      | 23; 22                                                        | 1800; 13% (age 22), 1387; 17% (age 23) | Wild type | 40 ± 20 μM/g | NA | NA; 13 cm | 140 | 141 | Bone marrow infiltration | none |
US) in five out of eight patients. Hepatomegaly was present in six out of eight patients, but in five cases co-factors for liver disease were detected. Anemia was present only in two out of eight patients and was mild in both cases. Only two out of eight patients reported bone pain at diagnosis, while bone involvement was demonstrated with subsequent imaging examinations in six out of eight patients.

2 | DISCUSSION

Gaucher Disease is a pleiotropic lysosomal storage disorder due to bi-allelic mutations in the GBA1 gene (1q21), or, in exceedingly rare cases, in the PSAP gene, which encodes for its activator protein (saposin C). Reduced or absent activity of β-glucocerebrosidase results in the accumulation of glucosylceramide in macrophages of several organs, mainly the spleen, liver, and bone marrow. The current phenotypic classification of GD into different subtypes is likely an oversimplification of a continuum of the same enzymatic defect that can be variably severe and clinically expressed. Such classification is based on the presence of central nervous system involvement, being type 1 the "non-neuronopathic", type 2 the "acute neuronopathic", and type 3 the "chronic neuronopathic" form of the disease. A certain degree of overlap is possible, particularly regarding the occurrence of Parkinsonism in GD1 patients. Gaucher Disease type 1 accounts for about 90% of all GD cases, and has a heterogeneous clinical expression, ranging from overt visceral and bone involvement in childhood/early-adulthood to more faded manifestations in late-adulthood. Unrecognized GD often leads to significant disability due to bone pain, fractures, and bleeding. N370S homozygosity in GBA1, the most common genotype in Ashkenazi Jewish, and the second most common one in European non-Jewish patients, is traditionally related to a mild phenotype but a clear genotype-phenotype correlation is lacking, and acquired factors can also influence the phenotype. The prevalence of GD, previously estimated at around 1:59000 [Meikle, JAMA 1999], has been recently questioned by data from newborn screening programs, suggesting a prevalence of near 1:22000, at least in North-

**FIGURE 3** Flow-chart for the differential diagnosis of hyperferritinemia based on clinical evaluation and first level tests: when to suspect a Gaucher Disease [Color figure can be viewed at wileyonlinelibrary.com]
East Italy. Indeed, such new findings have corroborated the belief that the disease is often under-recognized. The increasing availability of “dried blood spot” tools for widespread first-level analysis of enzymatic activity represents a useful help in the diagnostic process. The confirmation of low enzymatic activity is virtually diagnostic, and has almost completely superseded bone marrow examination, which could still be needed only when the clinical differential diagnosis includes a hematological malignancy. Noteworthy, effective treatments are available for GD1 and for non-neurological manifestations of GD3, that is, enzyme replacement therapy (ERT) and substrate-reduction therapy (SRT).

In such a context, it is essential to increase the awareness of the disease in order to make the right diagnosis as early as possible, hence reducing the disability burden. Hematologists are the specialists more likely involved in the diagnosis of GD, but, even when all classical clinical features are present, only a minority (~20%) of them consider GD in the differential diagnosis. Consultation of several specialists, misdiagnosis, and diagnostic delay are frequent features of the patient’s journey towards the correct diagnosis of GD, eventually resulting in a poor quality of life, complications, and sometimes irreversible disabilities. Common misdiagnoses include hematological malignancies, immune thrombocytopenic purpura, autoimmune disease, liver cirrhosis, idiopathic avascular necrosis, and “idiopathic” splenomegaly.

Since hematologic findings like splenomegaly, thrombocytopenia and anemia are among the most prevalent signs of GD, diagnostic algorithms starting from these findings have been proposed, with dedicated algorithms for subjects of Jewish ancestry due to the higher prevalence of GD. For example, the application of one of these algorithms to patients referred to Italian hematology outpatient clinics because of splenomegaly and/or thrombocytopenia detected GD in 7 out of 196 cases (prevalence 3.6%). Nonetheless, because of phenotypic heterogeneity and lack of awareness, other “high-risk patterns” need to be considered. Biochemical abnormalities commonly found in GD include hyperferritinemia, hypolipidemia with low HDL-cholesterol levels, low vitamin B12, polyclonal hypergammaglobulinemia, and MGUS.

Hyperferritinemia is a frequent finding in clinical practice, potentially associated with many different etiologies. Sometimes, it is due to IO, which may be genetic (eg, hereditary hemochromatosis caused by mutations in the HFE gene or in other genes involved in...
iron homeostasis), generally associated with increased TSat, or acquired (eg, due to repeated blood transfusions). More frequently, hyperferritinemia does not reflect a true IO, but it is due to inflammation, chronic liver disease, excessive alcohol intake, components of metabolic syndrome or malignancies. In these cases, TSat is usually normal. To make the correct diagnosis is essential because the management depends on the underlying disorder. Investigations of raised serum ferritin (ie, >200 μg/L in females, >300 μg/L in males) should include an accurate collection of patient’s medical history and some simple laboratory test, as summarized in Figure 3. In some cases, liver MRI or biopsy can be useful to assess liver iron stores. If hereditary hemochromatosis is suspected, a genetic analysis is recommended, including rare mutations in HFE and non-HFE genes (eg, HAMP, HJV, TFR2, BMP6, etc.) when a first-level genetic test is negative. Among the different causes of hyperferritinemia, GD is often overlooked. Hyperferritinemia (mean elevation 3-4 x upper limit of normal) with normal TSat is a common finding in naïve patients with type 1 GD.23 Recent case series reported a prevalence of 63-81%.7,8 While ferritin levels in GD patients can be markedly elevated, they are typically disproportioned with respect to liver iron accumulation, which is usually absent or unremarkable.23 For this reason, hyperferritinemia per se is not an indication for phlebotomies in GD patients, who may even experience worsening anemia and fatigue. Only sporadic cases reports in literature described significant iron deposits in GD patients, generally associated with cofactors like HFE mutations or chronic hepatitis C virus infection.23 An elevated TSat or liver iron accumulation at MRI can be of value in these rare cases.

Pathophysiology of hyperferritinemia in GD is still debated, and several explanations have been proposed, including long-lasting low-grade chronic inflammation, impaired function of macrophages involved in iron recycling, and local dysregulation of the hepcidin-ferroportin axis.7 Ferritin levels typically decrease during treatment, and have been proposed as a biomarker of disease activity,17 although not as meaningful as glucosylsphingosine, which directly reflects substrate accumulation.26 The GD specific treatment with ERT or SRT must be initiated according to international recommendations and consensus, not solely on the basis of mutation analysis and regardless of the ferritin levels.

Our series of 8 GD cases diagnosed at different Italian referral centers for iron disorders highlights the possibility of diagnosing GD starting from hyperferritinemia. In this context, even mild or incomplete classical manifestations of GD (ie, thrombocytopenia, splenomegaly, anemia, bone involvement) should lead to include GD in the differential diagnosis. Of note, our series shows that clinically mild phenotypes are not restricted to N370S homozygotes. In Figure 3 we propose a diagnostic flow-chart that could help physicians to detect GD when facing patients presenting with apparently “unexplained hyperferritinemia”. The combination of a careful clinical history with simple first level investigations may be sufficient for guiding a differential diagnosis, also including rare conditions, like GD. When GD is suspected, subsequent investigations should be tailored according to the strength of clinical suspicion. A DBS testing could be used as a first-line screening strategy, followed by confirmatory diagnostic approaches in the case of pathologic DBS results (Figure 4). Bone marrow examination may still play a role in the diagnostic process, particularly considering that GD per se is a risk factor for the development of hematological malignancies.

3  | CONCLUSIONS

Given the difficulties in diagnosis of type 1 GD in adults because of disease heterogeneity and lack of awareness, appropriate diagnostic algorithms or flow-charts starting from non-specific findings may help. Further studies may establish the usefulness of our proposed flow-chart in patients presenting with “unexplained hyperferritinemia”.

CONFLICT OF INTEREST

Giacomo Marchi has received fees for lectures from Shire-Takeda. Fabio Nascimbeni and Francesca Carubbi have received fees for consultancy or lectures from Sanofi-Genzyme and Shire-Takeda. Irene Motta has received honoraria and is a member of the advisory board for Sanofi-Genzyme. Maria Domenica Cappellini is a member of Vifor, Sanofi-Genzyme, Celgene, Novartis and Bluebird advisory board. Alberto Piperno has received fees for consultancy and lectures from Shire-Takeda. Domenico Girelli has received fees for lectures from Sanofi-Genzyme and Shire-Takeda. Fabiana Busti, Antonello Pietrangelo and Elena Corradini have nothing to declare.

ORCID

Giacomo Marchi https://orcid.org/0000-0002-4628-4825
Maria Domenica Cappellini https://orcid.org/0000-0001-8676-6864
Domenico Girelli https://orcid.org/0000-0001-9684-1899

REFERENCES

1. Riva A, Trombini P, Mariani R, et al. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J Gastroenterol. 2008;14(30):4745-4752. https://doi.org/10.3748/wjg.14.4745.
2. Pietrangelo A. Ferroportin disease: pathogenesis, diagnosis and treatment. Haematologica. 2017;102(12):1972-1984. https://doi.org/10.3324/haematol.2017.170720.
3. Mistry PK, Sadan S, Yang R, Yee J, Yee M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82(8):697-701.
4. Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type 1 Gaucher disease: an expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis. 2018;68:203-208. https://doi.org/10.1016/j.bcmd.2016.10.008.
5. Goker-Alpan O. Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab. 2011;104(4):438-447. https://doi.org/10.1016/j.ymgme.2011.08.004.
6. Nascimbeni F, Dalla Salda A, Carubbi F. Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease. Blood Cells Mol Dis. 2018b Feb;68:74-80. https://doi.org/10.1016/j.bcmd.2016.10.012.
7. Lefebvre T, Reihani N, Daher R, et al. Involvement of hepcidin in iron metabolism dysregulation in Gaucher disease. Hematologica. 2018;103(4):587-596. https://doi.org/10.3324/haematol.2017.177816.
8. Lorenz F, Pawlowicz E, Klimkowska M, et al. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type
1. Blood Cells Mol Dis. 2018;68:35-42. https://doi.org/10.1016/j.bcmd.2016.10.010.

9. Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. *Metabolic and Molecular Bases of Inherited Disease*. New York: McGraw-Hill; 2001:3635.

10. Linari S, Castaman G. Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab. 2015;12(2):157-164.

11. Riboldi MG, Di Fonzo AB. GBA, Gaucher disease and Parkinson’s disease: from genetic to clinic to new therapeutic approaches. Cells. 2019;8:364.

12. Fairley C, Zimran A, Phillips M, et al. Phenotypic heterogeneity of N370S homozygotes with type 1 Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. J Inherit Metab Dis. 2008 Dec;31(6):738-744. https://doi.org/10.1007/s10545-008-0868-z.

13. Nascimbeni F, Cassinerio E, Dalla Salda A, et al. Prevalence and predictors of liver fibrosis evaluated by vibration controlled transient elastography in type 1 Gaucher disease. Mol Genet Metab. 2018a;125(1-2):64-72. https://doi.org/10.1016/j.ymgme.2018.08.004.

14. Burlina AB, Polo G, Salvati L, et al. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2018;41(2):209-219. https://doi.org/10.1007/s10545-017-0098-3.

15. Chamoles NA, Blanco M, Gaggioli D, Casentini C. Gaucher and Niemann-Pick diseases—enzymatic diagnosis in dried blood spots on filter paper: retrospective diagnoses in newborn-screening cards. Clin Chim Acta. 2002;317(1-2):191-197.

16. Beutler E, Saven A. Misuse of marrow examination in the diagnosis of Gaucher disease. Blood. 1990;76:646-648.

17. Thomas AS, Mehta A, Hughes DA. Gaucher disease: haematological presentations and complications. Br J Haematol. 2014;165(4):427-440. https://doi.org/10.1111/bjh.12804.

18. Mehta A, Belmatoug N, Bembi B, et al. Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Mol Genet Metab. 2017;122(3):122-129. https://doi.org/10.1016/j.ymgme.2017.08.002.

19. Mistry PK, Cappellini MD, Lukina E, et al. Consensus Conference: A reappraisal of Gaucher disease - diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110-115. https://doi.org/10.1002/ajh.21888.

20. Motta I, Filocamo M, Poggiali E, et al. A multicentre observational study for early diagnosis of Gaucher disease in patients with Splenomegaly and/or Thrombocytopenia. Eur J Haematol. 2016;96(4):352-359. https://doi.org/10.1111/ejh.12596.

21. Aguilar-Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol. 2005;100(5):1185-1194.

22. Ong SY, Nicoll AJ, Delatycki MB. How should hyperferritinaemia be investigated and managed? Eur J Intern Med. 2016;33:21-27. https://doi.org/10.1016/j.ejim.2016.05.014.

23. Stein P, Yu H, Jain D, Mistry PK. Hyperferritinemia and iron overload in type 1 Gaucher disease. Am J Hematol. 2010;85(7):472-476. https://doi.org/10.1002/ajh.21721.

24.Rolfs A, Giese AK, Grittner U, et al. Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher Disease in a non-Jewish, Caucasian cohort of Gaucher Disease patients. PLoS One. 2013;8(11):e79732. https://doi.org/10.1371/journal.pone.0079732.

How to cite this article: Marchi G, Nascimbeni F, Motta I, et al. Hyperferritinemia and diagnosis of type 1 Gaucher disease. Am J Hematol. 2020;95:570–576. https://doi.org/10.1002/ajh.25752.